Turkey: Protection Of Second Medical Use Patents In Turkey

Introduction

It is commonly known that pharmaceutical patents cover the substance or the composition itself (molecule patents) and the use of this substance or composition in the treatment of a disease (indication patents).

In pharmaceutical patents, the new and non-obvious use of a known substance or composition for the manufacture of a medicament in the treatment of a specific disease is called as second or further medical use patents. The simplest example that can be mentioned for the second medical use patents is the patenting of an invention when a medicament with an active substance X known to be effective in the treatment of hypertension is also found to be effective in the treatment of common cold upon the further researches conducted.

1- Status of Second Medical Use in Turkey

In accordance with Transitional Article 4 of Decree Law No. 551 on the Protection of Patents (Decree Law No. 551), the protection pertaining to pharmaceutical products within the scope of this Decree Law commenced on January 1, 1999.

On the other hand Turkey signed the 1973 dated European Patent Convention (EPC 1973) on October 5, 1973, which provided protection for pharmaceutical patents. Although Turkey was one of the first states that signed the EPC 1973, this convention entered into force much later upon the publication of the law for accession to the convention and its annexes in the Official Gazette dated July 12, 2000.1

The act revising EPC 1973 was signed as a result of the diplomatic conference held in November 2000.2 This revision act is called EPC 2000. Turkey attended this diplomatic conference and signed the Revision Act. EPC 2000 which came into force on December 13, 2007; 2 years after the 15th contracting state deposited its instrument of ratification to the German Government.

Article 54/5 added to the convention by the EPC 2000 revision, explicitly states that specific use in any method referred to in Art. 53(c) provided that such use is not comprised in the state of the art, is patentable. According to this provision the use of a prior art substance and composition in the treatment of a new disease has become possible.

Despite the lack of a provision stating explicitly the patentability of second medical use patents in EPC 1973; it has been decided that the use of a known substance or composition for the manufacture of a medicament for a specific new and inventive therapeutic application is patentable by the G5/83 decision of the EPO Enlarged Board of Appeal.3

There have been opinions claiming that the G5/83 decision of the Enlarged Board of Appeal is not binding for the contracting states of the EPC and that the second medical use patents granted before December 13, 2007 - i.e before EPC 2000 came into force - are invalid.4

Contrary to the mentioned opinions, the authors of this article believe that, as far as Turkey is concerned, the decisions and opinions of the Enlarged Board of Appeal are the inseparable parts of the EPC 1973 because the Turkish Parliament acknowledged the developments with regard to the European Patent Convention since 1973 and approved the accession to the EPC 1973 on January 29, 2000 by ratifying it without any reservations. EPC 1973 and the decisions of the Enlarged Board of Appeal have been published together, in their entirety, in the Official Gazette. The fact that the Parliament acknowledged and voted the EPC 1973 together with the decisions of the Enlarged Board of Appeal without reservations; renders unquestionable the will of the Parliament to afford protection to patents covering second and further medical use on the basis of the international legislation of which Turkey is signatory and which has thus become national rule by Act of Parliament.

2- Evaluation of Second Medical Use Patents According to Decree Law No. 551 on the Protection of Patents:

Decree Law No.551 remains silent since second medical use patents are not accepted as "patentable" or "non-patentable". Neither there is a provision stating that second medical use patents are not subject to protection nor there is a distinction between first and second medical use patents in the Decree Law No. 551. Hence, in its practices, the Turkish Patent Institute grants second medical use patents provided that they meet the patentability criteria.

3- Evaluation of Second Medical Use Patents According to the TRIPs Agreement:

TRIPs does not indicate any prohibition for the protection of second medical use patents.

4- Evaluation of Second Medical Use Patents According to EPC 1973:

There is no provision in EPC 1973 that restricts patentability of inventions on second medical use.

According to Article 52 (1) of EPC 1973 titled "Patentable Inventions" "European patents shall be granted for any inventions which are susceptible of industrial application, which are new and which involve an inventive step."

Paragraph 2 of the same article states that "the following in particular shall not be regarded as inventions:

"(2) The following in particular shall not be regarded as inventions within the meaning of paragraph 1:

  1. discoveries, scientific theories and mathematical methods;
  2. aesthetic creations;
  3. schemes, rules and methods for performing mental acts, playing games or doing business, and programs for computers;
  4. presentations of information.

(3) The provisions of paragraph 2 shall exclude patentability of the subject-matter or activities referred to in that provision only to the extent to which a European patent application or European patent relates to such subject-matter or activities as such.

(4)* Methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practised on the human or animal body shall not be regarded as inventions which are susceptible of industrial application within the meaning of paragraph 1. This provision shall not apply to products, in particular substances or compositions, for use in any of these methods.

Ref: Art. 54, 56, 57, 100, 138

*See decisions of the Enlarged Board of Appeal G 1/83, G 5/83, G 6/83, G 1/98, G 1/03, G 2/03(Annex I).."

As understood from Article 52/4 above, this provision shall not be applied to methods for treatment of the human or animal body by surgery or therapy and diagnostic methods practiced on the human or animal body. This provision excludes the medical use of a substance or composition from non-patentable subject matters. There are no distinctions between first and second medical use patents.

In Article 53 titled "Exceptions to patentability" of EPC 1973 the subjects which shall not be patented are listed as follows:

"Article 53- Exceptions to patentability

European patents shall not be granted in respect of:

  1. inventions the publication or exploitation of which would be contrary to "ordre public" or morality, provided that the exploitation shall not be deemed to be so contrary merely because it is prohibited by law or regulation in some or all of the Contracting States;
  2. plant or animal varieties or essentially biological processes for the production of plants or animals; this provision does not apply to microbiological processes or the products thereof.

Ref: Art. 100, 138, 167*"

As shall be understood in the provisions of the article above, second medical use and medical use in general have not been listed among subjects that shall not be patented. Thus, there are no provisions stating that inventions subject to second medical use will not be protected in the scope of EPC 1973.

Article 54 of EPC 1973 titled "Novelty" reads:

"Article 54 - Novelty

  1. An invention shall be considered to be new if it does not form part of the state of the art.
  2. The state of the art shall be held to comprise everything made available to the public by means of a written or oral description, by use, or in any other way, before the date of filing of the European patent application.
  3. Additionally, the content of European patent applications as filed, of which the dates of filing are prior to the date referred to in paragraph 2 and which were published under Article 93 on or after that date, shall be considered as comprised in the state of the art.
  4. Paragraph 3 shall be applied only in so far as a Contracting State designated in respect of the later application, was also designated in respect of the earlier application as published.
  5. The provisions of paragraphs 1 to 4 shall not exclude the patentability of any substance or composition, comprised in the state of the art, for use in a method referred to in Article 52, paragraph 4, provided that its use for any method referred to in that paragraph is not comprised in the state of the art.

Ref: Art. 52, 55, 56, 80, 85, 89, 100, 138, 158, Rules 27, 44, 87

* See decisions/opinions of the Enlarged Board of

Appeal G 1/83, G 5/83, G 6/83, G 2/88, G 6/88,G 1/92, G 3/93 (Annex I)."

Paragraph 5 of this article explicitly accepts the use of a known substance or composition in a therapeutic application on the condition that it is new and inventive.

The G5/83 decision of the EPO Enlarged Board of Appeal is referenced in articles 52 and 54 of the EPC 1973.

The G5/83 decision is listed in the "Index of decisions and opinions of the Enlarged Board of Appeal published in the Official Journal of the EPO". The index of decisions and opinions is published as Annex-I of the EPC 1973 in the Official Gazette no. 24107 dated July 12, 2000. The index, relates the decision and opinion of the Enlarged Board of Appeal to the articles of the EPC 1973. The respective part of the index of decisions is quoted below:

Index of Decisions and Opinions of the Enlarged Board of Appeal Published in the Official Journal of the EPO
Case number, date, publication Title/Subject Article no., Rule no.
G 5/83
05.12.1984
European Patent Office Official Journal 1985, 64
"Second medical indication/EISAI" Interpretation of EPC/Vienna Convention – use claims regarding treatment Art. 52(1), 52(4), 54(5), 57 Articles 31, 32 of the Vienna Convention

The G5/83 decision of the EPO Enlarged Board of Appeal explains in detail how to interpret Articles 52 (4) and 54 (5) of the EPC 1973 and that a claim for the use of a known substance or composition in the manufacture of a medicament for a new therapeutic application is patentable.

The Turkish Parliament accepted the accession of Turkey to the EPC 1973 by the Act dated January 27, 2000 and No.: 4504. EPC 1973 entered into force upon its publication in the Official Gazette no. 24107 dated July 12, 2000.

It is obvious that the lawmaker namely the Parliament by the Act January 27, 2000 dates accepts the interpretation of the articles of EPC 1973 with the decisions and opinions of the Enlarged Board of Appeal which are published as inseparable annexes to the convention in the Turkish Official Gazette5. The aim of the lawmaker is that the interpretation of Articles 52 and 54 should be made in the light of the G5/83 decision which is an obvious annex of the Agreement to which Turkey is a party.

A contrary approach to EPC 1973, will be against the national legislation of Turkey and the provisions of the international conventions entered into force in Turkey and against Article 90/56 of the Constitution and Article 47 of the Decree Law No. 551.

Conclusion

As far as Turkey is concerned, the decisions and opinions of the Enlarged Board of Appeal are the inseparable parts of the EPC 1973 because the Turkish lawmaker observed the developments with regard to the European Patent Convention since 1973 approved and voted the accession to the EPC 1973 on January 29, 2000 by ratifying it without any reservations and publishing it in the Official Gazette in their entirety together with the Enlarged Board of Appeal decisions. Therefore second medical use patents should be protected in Turkey.

Footnotes

1. Official Gazette No. 24107 dated July 2, 2000:

http://www.resmigazete.gov.tr/main.aspx?home=http://www.resmigazete.gov.tr/eskiler/2000/07/20000712m1.htm&main=http://www.resmigazete.gov.tr/eskiler/2000/07/20000712m1.htm

2. ACT REVISING THE CONVENTION ON THE GRANT OF EUROPEAN PATENTS: http://documents.epo.org/projects/babylon/eponet.nsf/0/879B3BBE83D923B0C12572AE004FE772/$File/act_revising_epc_en.pdf

3. European Patent Office Official Journal, 1985, p. 060: G1/83 German, G5/83 English, G6/83 French

http://documents.epo.org/projects/babylon/eponet.nsf/0/5891FCEDA0C96A07C12572C8006C5110/$File/g830001.pdf

4. Hazal Zengingül, Ankara 2012, Fikri Mülkiyet Hukuku Yıllığı 2011, İkinci Tıbbi Kullanım Patentleri (Second Medical Use Patents), 447

Av. Ece Sarıca, Nisan 2015, İstanbul Barosu Dergisi Mart – Nisan 2015, Türkiye'de İkinci Tıbbi Kullanımın Patentlenmesi ve Korunması (Patenting and Protection of Second Medical Use in Turkey), 392

5. See footnote 1.

6. Article 90/5 of the 1982 Constitution of the Republic of Turkey: International agreements duly put into effect have the force of law. No appeal to the Constitutional Court shall be made with regard to these agreements, on the grounds that they are unconstitutional. In the case of a conflict between international agreements, duly put into effect, concerning fundamental rights and freedoms and the laws due to differences in provisions on the same matter, the provisions of international agreements shall prevail.

7. Article 4 of Decree Law No. 551: Where International Agreements having entered into force according to the laws of the Republic of Turkey, contain provisions which are preferential/more favorable to those of this present Decree-Law, the persons referred to in Article 2 may request to benefit from such preferential/more favorable provisions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Muazzez Korutürk
Okan Çan
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions